(Q39474834)

12 September 2017

title

Pharmacodynamics of DT-IgG, a dual-targeting antibody against VEGF-EGFR, in tumor xenografted mice (English)

1 reference

12 September 2017

1 reference

Selwyn J Hurwitz

1

1 reference

12 September 2017

Hongzheng Zhang

2

1 reference

12 September 2017

Sujin Yun

3

1 reference

12 September 2017

Thil D Batuwangala

4

1 reference

12 September 2017

Michael Steward

5

1 reference

12 September 2017

Steve D Holmes

6

1 reference

12 September 2017

Daniel Rycroft

7

1 reference

12 September 2017

Lin Pan

8

1 reference

12 September 2017

Mourad Tighiouart

9

1 reference

12 September 2017

Hyung Ju C Shin

10

1 reference

12 September 2017

Lydia Koenig

11

1 reference

12 September 2017

Yuxiang Wang

12

1 reference

12 September 2017

Zhuo Georgia Chen

13

1 reference

12 September 2017

Dong M Shin

14

1 reference

12 September 2017

publication date

13 September 2011

1 reference

Cancer Chemotherapy and Pharmacology

12 September 2017

published in

1 reference

12 September 2017

volume

69

1 reference

12 September 2017

issue

3

1 reference

12 September 2017

page(s)

577-590

1 reference

Managing tumor angiogenesis: lessons from VEGF-resistant tumors and wounds

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1713-X

FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1713-X

Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1713-X

The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1713-X

Managing patients treated with bevacizumab combination therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1713-X

Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1713-X

Intricacies of bevacizumab-induced toxicities and their management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1713-X

Adverse effects of anticancer agents that target the VEGF pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1713-X

Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1713-X

Epidermal growth factor-related peptides and their receptors in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1713-X

EGFR signaling and drug discovery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1713-X

The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1713-X

Cetuximab: from bench to bedside.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1713-X

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1713-X

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1713-X

Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1713-X

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1713-X

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1713-X

Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1713-X

Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1713-X

A mathematical model to study the effects of drugs administration on tumor growth dynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1713-X

A mathematical model of breast and ovarian cancer treated with paclitaxel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1713-X

Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1713-X

Demonstration of the equivalent pharmacokinetic/pharmacodynamic dosing strategy in a multiple-dose study of gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1713-X

Modeling of tumor growth and anticancer effects of combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1713-X

A minimal model of tumor growth inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1713-X

A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1713-X

Domain antibodies: proteins for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1713-X

High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1713-X

Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1713-X

Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1713-X

Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1713-X

Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1713-X

Pharmacokinetics of rapacuronium in infants and children with intravenous and intramuscular administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1713-X

Regional differences in the growth of normal and neoplastic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1713-X

Alternative dosing schedules for cetuximab: a role for biweekly administration?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1713-X

10.1007/S00280-011-1713-X

21 January 2018

Identifiers

DOI

1 reference

12 September 2017

1 reference